Valcarcel S, Gallego J, Jimenez-Fonseca P, Diez M, et al. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. J Cancer Res Clin Oncol 2023;149:4077-4089.
PMID: 36042046